RIGEL PHARMACEUTICALS, INC. Research and Development Expense
RIGEL PHARMACEUTICALS, INC. (RIGL) reported Research and Development Expense of $13.96 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-04
- RIGEL PHARMACEUTICALS, INC. research and development expense for the quarter ending 2026-06-30 was $13.96M, a 104.68% increase year-over-year.
- RIGEL PHARMACEUTICALS, INC. research and development expense for the quarter ending 2026-03-31 was $11.68M, a 38.41% increase year-over-year.
- RIGEL PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-06-30 was $6.82M.
- RIGEL PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-03-31 was $8.44M.
- RIGEL PHARMACEUTICALS, INC. research and development expense for fiscal 2025 was $33.30M, a 42.41% increase from fiscal 2024.
- RIGEL PHARMACEUTICALS, INC. research and development expense for fiscal 2024 was $23.38M, a 4.66% decline from fiscal 2023.
- RIGEL PHARMACEUTICALS, INC. research and development expense for fiscal 2023 was $24.52M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 12 month |
|---|---|---|---|
| 2026-06-30 | $13.96M 10-Q · filed 2026-08-04 | $25.64M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $11.68M 10-Q · filed 2026-05-05 | ||
| 2025-12-31 | $33.30M 10-K · filed 2026-03-03 | ||
| 2025-06-30 | $6.82M 10-Q · filed 2026-08-04 | $15.26M 10-Q · filed 2026-08-04 | |
| 2025-03-31 | $8.44M 10-Q · filed 2026-05-05 | ||
| 2024-12-31 | $23.38M 10-K · filed 2026-03-03 | ||
| 2023-12-31 | $24.52M 10-K · filed 2026-03-03 | ||
| 2011-06-30 | $17.11M 10-Q · filed 2011-08-02 | $32.22M 10-Q · filed 2011-08-02 | |
| 2010-06-30 | $16.82M 10-Q · filed 2011-08-02 | $34.24M 10-Q · filed 2011-08-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |